January 29, 2016 – For women undergoing breast cancer surgery, a technique called lipofilling–using the patient's own fat cells to optimize the results of breast reconstruction–does not increase the risk of recurrent breast cancer, reports a study in the February issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).
"Our controlled study shows that, used as part of breast reconstruction, lipofilling is a safe procedure that does not increase the risk of recurrent or new breast cancers," comments ASPS member surgeon Dr. Steven J. Kronowitz of Kronowitz Plastic Surgery, Houston (formerly of M.D. Anderson Cancer Center), lead author of the new report.
New Evidence That Lipofilling Is Safe for Breast Reconstruction
Using a plastic surgery database, the researchers analyzed a series of more than 1,000 partial or total mastectomies followed by breast reconstruction with lipofilling. About 30 percent of cases involved risk-reducing mastectomy in women at high genetic risk of breast cancer.
Rates of recurrent or new breast cancers were then compared with a similar group of women who underwent mastectomy followed by breast reconstruction without lipofilling. In the lipofilling procedure, fat obtained by liposuction from one part of the body–for example, the abdomen or thighs–is injected to enhance the appearance of the breast.
For women who underwent mastectomy for breast cancer, overall recurrence rates were similar for reconstruction with versus without lipofilling. The rate of locoregional recurrence (in the breast and surrounding area) was not significantly different between groups: 1.3 percent for women who had lipofilling versus 2.4 percent in those who did not.
Rates of systemic (distant) cancer recurrence were similar as well: 2.4 percent with lipofilling versus 3.6 percent without. None of the women undergoing preventive mastectomy developed initial (primary) breast cancer.
In most patient subgroups, breast cancer recurrence risk was similar with or without lipofilling. The sole exception was women receiving hormone therapy, for whom lipofilling was associated with a small but significant increase in locoregional recurrence risk: 1.4 versus 0.5 percent.
Lipofilling is a fat grafting technique that is increasingly used to optimize the cosmetic results of breast reconstruction. In a 2013 survey, more than 60 percent of ASPS member surgeons said they used fat grafting as part of breast reconstruction.
But some plastic surgeons may still be reluctant to use lipofilling because of concern that it might affect the risk of primary or recurrent breast cancer. The new study of breast cancer recurrence risk associated with lipofilling is the first to use a control group of women who underwent breast reconstruction without lipofilling.
The results show no increase in the risk of locoregional or systemic recurrence in women with breast cancer who undergo breast reconstruction with lipofilling. The study also finds no evidence that lipofilling affects the risk of initial breast cancer for the growing number of high-risk women undergoing "preventive" mastectomy.
"Our results provide new evidence that lipofilling, used as part of breast reconstruction, is a safe procedure that does not increase the risk of recurrent or new breast cancer after mastectomy," Dr. Kronowitz comments. While highlighting the need for further research, the researchers hope their findings will encourage more plastic surgeons to use lipofilling to provide the best possible results of breast reconstruction for their patients undergoing breast cancer surgery.
Click here to read "Lipofilling of the Breast Does Not Increase the Risk of Recurrence of Breast Cancer: A Matched Controlled Study."
Article: "Lipofilling of the Breast Does Not Increase the Risk of Recurrence of Breast Cancer: A Matched Controlled Study" (doi: 10.1097/01.prs.0000475741.32563.50)
Plastic and Reconstructive Surgery® is published by Wolters Kluwer.
About Plastic and Reconstructive Surgery
For more than 60 years, Plastic and Reconstructive Surgery® (http://journals.lww.com/plasreconsurg/) has been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon. The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery® brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues.
The American Society of Plastic Surgeons (ASPS) is the world's largest organization of board-certified plastic surgeons. Representing more than 7,000 Member Surgeons, the Society is recognized as a leading authority and information source on aesthetic and reconstructive plastic surgery. ASPS comprises more than 94 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada. ASPS advances quality care to plastic surgery patients by encouraging high standards of training, ethics, physician practice and research in plastic surgery. You can learn more and visit the American Society of Plastic Surgeons at http://www.plasticsurgery.org or http://www.facebook.com/PlasticSurgeryASPS and http://www.twitter.com/ASPS_news.
About Wolters Kluwer
Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2014 annual revenues of €3.7 billion. The group serves customers in over 170 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on NYSE Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
For more information about our products and organization, visit http://www.wolterskluwerhealth.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.